No Data
Express News | Theratechnologies Resumes Production Of EGRIFTA SV Following Shutdown Of Facility To Address FDA Inspection
Theratechnologies Announces Resumed Production of EGRIFTA SV
Theratechnologies Brief: Says "Favourable" Interest Rates and Amortization Schedules to Free up Near $19 Million in Cash in 2025 "To Support Business Development Strategy"
Theratechnologies Brief: Secures up to $75 Million in New Credit Facilities With TD Bank and Investissement Quebec
Theratechnologies Secures up to $75 Million in New Credit Facilities With TD Bank and Investissement Québec
Theratechnologies Resubmits SBLA For F8 Formulation Of Tesamorelin; Decision Expected By March 2025
No Data